» Articles » PMID: 37348094

Executive Summary of the Ovarian Cancer Evidence Review Conference

Overview
Journal Obstet Gynecol
Date 2023 Jun 22
PMID 37348094
Authors
Affiliations
Soon will be listed here.
Abstract

The Centers for Disease Control and Prevention awarded funding to the American College of Obstetricians and Gynecologists to develop educational materials for clinicians on gynecologic cancers. The American College of Obstetricians and Gynecologists convened a panel of experts in evidence review from the Society for Academic Specialists in General Obstetrics and Gynecology and content experts from the Society of Gynecologic Oncology to review relevant literature, best practices, and existing practice guidelines as a first step toward developing evidence-based educational materials for women's health care clinicians about ovarian cancer. Panel members conducted structured literature reviews, which were then reviewed by other panel members and discussed at a virtual meeting of stakeholder professional and patient advocacy organizations in February 2022. This article is the executive summary of the relevant literature and existing recommendations to guide clinicians in the prevention, early diagnosis, and special considerations of ovarian cancer. Substantive knowledge gaps are noted and summarized to provide guidance for future research.

Citing Articles

Few-Layer Graphene-Based Optical Nanobiosensors for the Early-Stage Detection of Ovarian Cancer Using Liquid Biopsy and an Active Learning Strategy.

Covarrubias-Zambrano O, Agarwal D, Lewis-Wambi J, Neri R, Jewell A, Natarajan B Cells. 2025; 14(5).

PMID: 40072103 PMC: 11898886. DOI: 10.3390/cells14050375.


Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens.

Gaumond S, Beraja G, Kamholtz I, Ferrari L, Mahmoud R, Jimenez J Cancers (Basel). 2025; 17(3).

PMID: 39941780 PMC: 11816305. DOI: 10.3390/cancers17030411.


FOXR2 in cancer development: emerging player and therapeutic opportunities.

Yang P, Sheykhhasan M, Heidari R, Chamanara M, Dama P, Ahmadieh-Yazdi A Oncol Res. 2025; 33(2):283-300.

PMID: 39866234 PMC: 11753994. DOI: 10.32604/or.2024.052939.


Personality traits of women with hereditary risk for breast/ovarian cancer versus obstetric history and cancer preventive behaviors.

Zurawska J, Pieta B, Wilczak M, Wojciechowska M, Rzymski P, Pieczykolan A Sci Rep. 2025; 15(1):3218.

PMID: 39863726 PMC: 11762286. DOI: 10.1038/s41598-025-87657-6.


RBN-2397, a PARP7 Inhibitor, Synergizes with Paclitaxel to Inhibit Proliferation and Migration of Ovarian Cancer Cells.

Spirtos A, Aljardali M, Challa S, Koul S, Lea J, Kraus W bioRxiv. 2024; .

PMID: 39229139 PMC: 11370341. DOI: 10.1101/2024.08.20.608802.


References
1.
Quirk J, Natarajan N . Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol. 2005; 97(2):519-23. DOI: 10.1016/j.ygyno.2005.02.007. View

2.
Harmsen M, Arts-De Jong M, Hoogerbrugge N, Maas A, Prins J, Bulten J . Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study. BMC Cancer. 2015; 15:593. PMC: 4541725. DOI: 10.1186/s12885-015-1597-y. View

3.
Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P . Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv1-iv18. DOI: 10.1093/annonc/mdy001. View

4.
Marchetti C, De Felice F, Perniola G, Lecce F, Vertechy L, Monti M . Screening program in ovarian cancer: A logical step in clinical management? A meta-analysis. Curr Probl Cancer. 2018; 42(2):235-240. DOI: 10.1016/j.currproblcancer.2017.12.005. View

5.
van Nagell Jr J, Burgess B, Miller R, Baldwin L, DeSimone C, Ueland F . Survival of Women With Type I and II Epithelial Ovarian Cancer Detected by Ultrasound Screening. Obstet Gynecol. 2018; 132(5):1091-1100. PMC: 9373050. DOI: 10.1097/AOG.0000000000002921. View